image
Healthcare - Medical - Instruments & Supplies - NYSE - US
$ 31.96
0.82 %
$ 16.3 B
Market Cap
127.84
P/E
1. INTRINSIC VALUE

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories.[ Read More ]

The intrinsic value of one BAX stock under the base case scenario is HIDDEN Compared to the current market price of 32 USD, Baxter International Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart BAX

image
FINANCIALS
14.8 B REVENUE
-1.99%
390 M OPERATING INCOME
171.04%
-69 M NET INCOME
97.15%
1.73 B OPERATING CASH FLOW
42.53%
3.21 B INVESTING CASH FLOW
445.11%
-3.49 B FINANCING CASH FLOW
-142.63%
2.7 B REVENUE
-29.20%
-5 M OPERATING INCOME
97.40%
149 M NET INCOME
147.45%
-278 M OPERATING CASH FLOW
-241.74%
-24 M INVESTING CASH FLOW
73.63%
-146 M FINANCING CASH FLOW
84.40%
Balance Sheet Decomposition Baxter International Inc.
image
Current Assets 9.6 B
Cash & Short-Term Investments 3.19 B
Receivables 2.74 B
Other Current Assets 3.66 B
Non-Current Assets 18.7 B
Long-Term Investments 374 M
PP&E 4.96 B
Other Non-Current Assets 13.3 B
Current Liabilities 6.5 B
Accounts Payable 1.24 B
Short-Term Debt 2.8 B
Other Current Liabilities 2.47 B
Non-Current Liabilities 13.3 B
Long-Term Debt 11.5 B
Other Non-Current Liabilities 1.8 B
EFFICIENCY
Earnings Waterfall Baxter International Inc.
image
Revenue 14.8 B
Cost Of Revenue 9.84 B
Gross Profit 4.98 B
Operating Expenses 5.27 B
Operating Income 390 M
Other Expenses 459 M
Net Income -69 M
RATIOS
33.59% GROSS MARGIN
33.59%
2.63% OPERATING MARGIN
2.63%
17.93% NET MARGIN
17.93%
31.61% ROE
31.61%
9.39% ROA
9.39%
1.18% ROIC
1.18%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Baxter International Inc.
image
Net Income -69 M
Depreciation & Amortization 1.26 B
Capital Expenditures -692 M
Stock-Based Compensation 133 M
Change in Working Capital 268 M
Others 971 M
Free Cash Flow 1.03 B
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Baxter International Inc.
image
Wall Street analysts predict an average 1-year price target for BAX of $40 , with forecasts ranging from a low of $30 to a high of $45 .
BAX Lowest Price Target Wall Street Target
30 USD -6.13%
BAX Average Price Target Wall Street Target
40 USD 25.16%
BAX Highest Price Target Wall Street Target
45 USD 40.80%
4. DIVIDEND ANALYSIS
0.76% DIVIDEND YIELD
0.29 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Baxter International Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
2.62 M USD 1
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
8 months ago
Mar 01, 2024
Sell 2.62 M USD
Mason Jeanne K
EVP, Chief HR Officer
- 64488
40.61 USD
1 year ago
Mar 20, 2023
Sell 147 K USD
STROUCKEN ALBERT P L
Director
- 3930
37.52 USD
1 year ago
Feb 21, 2023
Sell 154 K USD
Kunzler Jacqueline
SVP, Chief Quality Officer
- 3813
40.5 USD
1 year ago
Jan 17, 2023
Sell 2.66 M USD
Mason Jeanne K
SVP, Human Resources
- 59477
44.7 USD
2 years ago
Apr 05, 2022
Sell 213 K USD
STROUCKEN ALBERT P L
Director
- 2805
75.76 USD
2 years ago
Apr 05, 2022
Sell 93.1 K USD
STROUCKEN ALBERT P L
director:
- 1215
76.63 USD
2 years ago
Apr 05, 2022
Sell 214 K USD
HELLMAN PETER S
director:
- 2827
75.76 USD
2 years ago
Apr 05, 2022
Sell 91.4 K USD
HELLMAN PETER S
Director
- 1193
76.63 USD
2 years ago
Apr 01, 2022
Sell 78.1 K USD
FORSYTH JOHN D
director:
- 1005
77.68 USD
2 years ago
Mar 01, 2022
Sell 85.2 K USD
FORSYTH JOHN D
Director
- 1005
84.82 USD
2 years ago
Feb 28, 2022
Sell 199 K USD
Stevens Brian
SVP, CAO and Controller
- 2325
85.46 USD
2 years ago
Feb 28, 2022
Sell 15.1 K USD
Stevens Brian
SVP, CAO and Controller
- 175
86.07 USD
2 years ago
Feb 14, 2022
Sell 3.04 M USD
Mason Jeanne K
SVP, Human Resources
- 35841
84.75 USD
2 years ago
Feb 14, 2022
Sell 1.57 M USD
Mason Jeanne K
SVP, Human Resources
- 18302
85.54 USD
2 years ago
Feb 02, 2022
Sell 142 K USD
Chen Thomas F
Director
- 1680
84.53 USD
2 years ago
Feb 01, 2022
Sell 86 K USD
FORSYTH JOHN D
Director
- 1005
85.59 USD
3 years ago
Nov 01, 2021
Sell 1.58 M USD
Martin Sean
SVP and General Counsel
- 19876
79.53 USD
3 years ago
Nov 01, 2021
Sell 126 K USD
Martin Sean
SVP and General Counsel
- 1574
80.03 USD
3 years ago
Aug 02, 2021
Sell 1.53 M USD
Martin Sean
SVP and General Counsel
- 19800
77.26 USD
3 years ago
Apr 12, 2021
Sell 933 K USD
Frye Andrew
SVP, President, APAC
- 10999
84.79 USD
3 years ago
Apr 05, 2021
Sell 422 K USD
STROUCKEN ALBERT P L
Director
- 4990
84.56 USD
3 years ago
Apr 05, 2021
Sell 422 K USD
HELLMAN PETER S
Director
- 4990
84.56 USD
4 years ago
Nov 02, 2020
Sell 2.87 M USD
Martin Sean
SVP and General Counsel
- 36608
78.52 USD
4 years ago
Nov 02, 2020
Sell 823 K USD
Martin Sean
SVP and General Counsel
- 10393
79.22 USD
4 years ago
Sep 14, 2020
Sell 25.9 K USD
FORSYTH JOHN D
Director
- 310
83.59 USD
4 years ago
Aug 03, 2020
Sell 996 K USD
GAVIN JAMES R III
Director
- 11548
86.26 USD
4 years ago
Aug 03, 2020
Sell 291 K USD
GAVIN JAMES R III
Director
- 3351
86.91 USD
4 years ago
Jun 19, 2020
Sell 6.15 M USD
Accogli Giuseppe
SVP, President, Americas
- 72341
85 USD
4 years ago
Jun 15, 2020
Sell 124 K USD
FORSYTH JOHN D
Director
- 1500
82.95 USD
4 years ago
Jun 08, 2020
Sell 2.09 M USD
Franzi Cristiano
SVP, President, EMEA
- 23900
87.33 USD
4 years ago
Jun 08, 2020
Sell 2 M USD
Franzi Cristiano
SVP, President, EMEA
- 22700
87.96 USD
4 years ago
Jun 03, 2020
Sell 341 K USD
Frye Andrew
SVP, President, APAC
- 3742
91 USD
4 years ago
Apr 27, 2020
Sell 3.58 M USD
Mason Jeanne K
SVP, Human Resources
- 38477
92.99 USD
4 years ago
Apr 27, 2020
Sell 813 K USD
Mason Jeanne K
SVP, Human Resources
- 8669
93.74 USD
4 years ago
Apr 01, 2020
Sell 102 K USD
STROUCKEN ALBERT P L
Director
- 1300
78.79 USD
4 years ago
Apr 01, 2020
Sell 242 K USD
STROUCKEN ALBERT P L
Director
- 3020
80 USD
4 years ago
Apr 01, 2020
Sell 142 K USD
HELLMAN PETER S
Director
- 1800
79.05 USD
4 years ago
Apr 01, 2020
Sell 202 K USD
HELLMAN PETER S
Director
- 2520
80.1 USD
4 years ago
Mar 30, 2020
Bought 804 K USD
Martin Sean
SVP and General Counsel
+ 9780
82.19 USD
4 years ago
Mar 18, 2020
Sell 115 K USD
FORSYTH JOHN D
Director
- 1500
76.7 USD
4 years ago
Dec 13, 2019
Sell 125 K USD
FORSYTH JOHN D
Director
- 1500
83.64 USD
5 years ago
Oct 14, 2019
Sell 293 K USD
Frye Andrew
SVP, President, APAC
- 3332
88 USD
5 years ago
Sep 13, 2019
Sell 15.8 K USD
FORSYTH JOHN D
Director
- 180
87.76 USD
5 years ago
Sep 05, 2019
Sell 523 K USD
Kunzler Jacqueline
SVP, Chief Quality Officer
- 5934
88.12 USD
5 years ago
Aug 19, 2019
Sell 697 K USD
GAVIN JAMES R III
Director
- 7950
87.63 USD
5 years ago
Jun 19, 2019
Sell 47.7 K USD
Kunzler Jacqueline
SVP, Chief Quality Officer
- 593
80.46 USD
5 years ago
Jun 13, 2019
Sell 103 K USD
FORSYTH JOHN D
Director
- 1320
78.21 USD
5 years ago
May 16, 2019
Sell 382 M USD
Third Point LLC
Director
- 5000000
76.37 USD
5 years ago
May 01, 2019
Sell 76.2 K USD
STALLKAMP THOMAS T
Director
- 1000
76.2 USD
5 years ago
Apr 01, 2019
Sell 465 K USD
STROUCKEN ALBERT P L
Director
- 5680
81.89 USD
5 years ago
Apr 01, 2019
Sell 85.6 K USD
STALLKAMP THOMAS T
Director
- 1043
82.07 USD
5 years ago
Apr 01, 2019
Sell 465 K USD
HELLMAN PETER S
Director
- 5680
81.89 USD
5 years ago
Mar 29, 2019
Sell 777 K USD
Pleau Scott
SVP, Operations
- 9710
80 USD
5 years ago
Mar 18, 2019
Sell 2.94 M USD
Accogli Giuseppe
SVP, President, Global Bus.
- 38297
76.78 USD
5 years ago
Mar 13, 2019
Sell 114 K USD
FORSYTH JOHN D
Director
- 1500
75.92 USD
5 years ago
Mar 01, 2019
Sell 75.2 K USD
STALLKAMP THOMAS T
Director
- 1000
75.16 USD
5 years ago
Feb 01, 2019
Sell 121 K USD
STALLKAMP THOMAS T
Director
- 1638
73.75 USD
7. News
Baxter to Present at Jefferies London Healthcare Conference DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024. Joel Grade, Baxter's chief financial officer, is scheduled to present at 11:00 a.m. Greenwich Mean Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through Monday, May 19, 2025. About Baxter Every day, millions of patients and caregivers rely o. businesswire.com - 3 days ago
Baxter to Present at Stifel 2024 Healthcare Conference DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Stifel 2024 Healthcare Conference on Monday, November 18, 2024. Joel Grade, Baxter's chief financial officer, is scheduled to present at 8:35 a.m. Eastern Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through Saturday, May 17, 2025. About Baxter Every day, millions of patients and caregivers rely on Baxter's lea. businesswire.com - 4 days ago
Baxter Declares Quarterly Dividend DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.17 per share of common stock. The dividend is payable on Jan. 2, 2025, to stockholders of record as of Nov. 29, 2024. The indicated annual dividend rate is $0.68 per share of common stock. This dividend represents the new quarterly dividend rate for Baxter in anticipation of the divestiture of its Kidney Care bu. businesswire.com - 5 days ago
Baxter International Inc. (BAX) Q3 2024 Earnings Call Transcript Baxter International Inc. (NYSE:BAX ) Q3 2024 Earnings Conference Call November 8, 2024 8:30 AM ET Company Participants Clare Trachtman - Senior Vice President, Chief Investor Relations Officer Joe Almeida - Chairman, President and Chief Executive Officer Joel Grade - Executive Vice President and Chief Financial Officer Conference Call Participants Travis Steed - Bank of America Securities Robert Marcus - JPMorgan Pito Chickering - Deutsche Bank Vijay Kumar - Evercore ISI Joanne Wuensch - Citi Lawrence Biegelsen - Wells Fargo David Roman - Goldman Sachs Operator Good morning, ladies and gentlemen, and welcome to Baxter International's Third Quarter 2024 Earnings Conference Call. Your lines will remain in a listen-only mode until the question-and-answer segment of today's call. seekingalpha.com - 1 week ago
BAX Stock Falls Despite Q3 Earnings & Sales Beat, Margins Decline Baxter reports better-than-expected third-quarter results. However, the company's gross and operating margins contract. zacks.com - 1 week ago
Baxter (BAX) Reports Q3 Earnings: What Key Metrics Have to Say Although the revenue and EPS for Baxter (BAX) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. zacks.com - 1 week ago
Baxter International (BAX) Beats Q3 Earnings Estimates Baxter International (BAX) came out with quarterly earnings of $0.80 per share, beating the Zacks Consensus Estimate of $0.78 per share. This compares to earnings of $0.68 per share a year ago. zacks.com - 1 week ago
Baxter cuts annual profit forecast on hurricane impact Baxter International cut its annual profit forecast on Friday due to a hurricane-related hit to its intravenous solutions facility, sending its shares down 3.3% in premarket trading. reuters.com - 1 week ago
Baxter Reports Third-Quarter 2024 Results DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the third quarter of 2024. “Baxter delivered positive performance in the third quarter of 2024, as the company continues to execute against its strategic transformation,” said José (Joe) E. Almeida, chair, president and chief executive officer. “The pending sale of our Kidney Care business represents another defining milestone in our ongoing transformation journey. We are. businesswire.com - 1 week ago
Strong Demand and Positive Pricing to Drive Baxter's Q3 Earnings BAX's third-quarter results are likely to benefit from a positive pricing impact and new product launches. However, supply-chain issues are likely to have raised expenses in the quarter. zacks.com - 1 week ago
Countdown to Baxter (BAX) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS Evaluate the expected performance of Baxter (BAX) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight. zacks.com - 1 week ago
Kontoor Brands CEO Scott Baxter on Q3 earnings beat Scott Baxter, Kontoor Brands CEO, joins CNBC's 'The Exchange' to discuss Kontoor's third-quarter earnings beat, the growth of the company through marketing, and more. youtube.com - 2 weeks ago
8. Profile Summary

Baxter International Inc. BAX

image
COUNTRY US
INDUSTRY Medical - Instruments & Supplies
MARKET CAP $ 16.3 B
Dividend Yield 0.76%
Description Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
Contact One Baxter Parkway, Deerfield, IL, 60015 https://www.baxter.com
IPO Date Oct. 27, 1981
Employees 60000
Officers Mr. David S. Rosenbloom Executive Vice President & General Counsel Mr. Charles Rusty Patel Senior Vice President & Chief Information Officer Mr. Christopher A. Toth Executive Vice President & Group President of Kidney Care Ms. Stacey Eisen Senior Vice President, Chief Communications Officer & Corporate Marketing? Ms. Heather Knight Executive Vice President & Group President of Medical Products and Therapies Ms. Clare Trachtman Vice President of Investor Relations Ms. Tobi Karchmer M.D., M.S. Senior Vice President and Chief Medical & Scientific Officer Mr. Joel T. Grade Executive Vice President, Chief Financial Officer & Interim Chief Accounting Officer Mr. Alok Sonig B.E., Mba Executive Vice President & Group President of Pharmaceuticals Mr. Jose E. Almeida Chairman of the Board, President & Chief Executive Officer